WHO Launches Updated Framework for Testing Genetically Modified Mosquitoes
The World Health Organization Special Program for Research and Training in Tropical Diseases, and the Foundation for the National Institutes of Health launched an updated framework for testing genetically modified mosquitoes as a way to foster quality and consistency in the processes for testing and regulating new genetic technologies.
Despite ongoing control efforts, diseases transmitted by mosquitoes, such as malaria and dengue, continue to be an enormous global health burden, as vector-borne diseases are endemic in more than 100 countries and affect approximately half of the world’s population.
For more than two decades, scientists have been working to harness the promise of molecular biology to develop genetically modified mosquitoes for use as public health tools to prevent the transmission of these diseases.
Previously available methods to control mosquito vectors of malaria and dengue were based on the use of insecticides and elimination of mosquito larval breeding sites, and radiation and chemo-sterilization methods.
However, these methods posed difficulties, such as the dependence on a limited number of insecticides for vector control increased the risk that mosquitoes would develop resistance.
GMMs hold the promise of being a more effective way to reduce the number of mosquito vectors in a given region or render the local mosquitoes unable to transmit a pathogen because they can reach mosquito populations and mosquito larval breeding sites, which have traditionally been the hardest and most expensive to access, by exploiting the natural behavior of mosquitoes to mate and seek sites for egg laying.
GMMs are also better suited for urban settings, where current control measures are largely ineffective due to the wide availability of cryptic mosquito larval breeding sites.
There is also potential for GMMs to reach outdoor and day-biting mosquitoes that often escape control methods such as bed nets and indoor insecticide spraying, and allow researchers to target specific mosquito species, which would avoid ecological and environmental hazards associated with insecticides and provide continuous protection in situations where other disease control methods have been interrupted to prevent the reintroduction of the pathogen after successful elimination efforts.
In The News
Vaccine maker Novavax said Monday its COVID-19 shot was highly effective against the disease and also protected against variants in a large study in the U.S. and Mexico, potentially offering the world yet another weapon against the virus at a time when developing countries are desperate... Read More
CAPE TOWN, South Africa (AP) — U.S. plans to donate 500 million more COVID-19 vaccines to developing countries were met Thursday with both celebration and hesitation amid questions over whether the effort will be enough to help poor regions desperate for doses. Some health officials and... Read More
The FDA has authorized the first aid for diagnosing Autism Spectrum Disorder in children 18 months through 5 years of age called Canvas Dx. It was developed by Cognoa, a behavioral health company. “Currently, pediatricians refer most children with suspected developmental delay to specialists to diagnose... Read More
Why do some people get side effects after COVID-19 vaccines? Temporary side effects including headache, fatigue and fever are signs the immune system is revving up -- a normal response to vaccines. And they're common. "The day after getting these vaccines, I wouldn't plan anything that... Read More
Rep. Tom O’Halleran, D-Ariz., has joined Rep. Jodey Arrington, R- Texas, and a bipartisan group of members in a drive to improve the performance standards for health care providers who participate in Medicare’s Accountable Care Organizations, which are part of the Medicare Shared Savings Program. “For... Read More
The Supreme Court this week decided to leave in place a $2 billion verdict in favor of women who claim they developed ovarian cancer from using Johnson & Johnson talc products. As is their custom, the justices did not comment Tuesday on why they rejected Johnson & Johnson's... Read More